SHINE Technologies, LLC is sharing an important update: “SHINE Receives Conditional Commitment for $263 Million DOE Loan to Scale Domestic Medical Isotope Manufacturing Using Fusion Technology“. Read the full release below:

SHINE received a Conditional Commitment for $263 Million DOE Loan to complete the world's largest medical isotope production facility—and it's the first deployment of new nuclear technology at this scale in decades.It's fusion operating commercially, producing medical isotopes for 40,000+ daily procedures while generating actual revenue. The Janesville, WI facility uses a recyclable liquid uranium target instead of the solid, single-use targets in conventional production. Worth watching: SHINE is proving you can commercialize fusion by solving today's problems, not waiting for breakthrough energy tech.

The U.S. Department of Energy has made a conditional commitment to advance the commercialization of fusion technology in the United States — a $263 million loan to complete SHINE's Chrysalis.

US imports 100% of Mo-99 from aging reactors. 40K+ daily medical procedures depend on it. SHINE gets $263M conditional DOE financing to establish 1st domestic commercial supply using fusion technology. 1st new nuclear deployment at this scale in decades.